Cargando...

AT-39 A RANDOMIZED PHASE II TRIAL OF VANDETANIB (ZD6474) IN COMBINATION WITH CARBOPLATIN VERSUS CARBOPLATIN ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA

BACKGROUND: Vandetanib is a tyrosine kinase inhibitor of VEGFR-2, EGFR, and the RET oncogene. While vandetanib has not shown significant clinical activity, preclinical experience suggests synergistic efficacy in combination with carboplatin in glioblastoma (GBM). METHODS: This randomized non-compara...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: McNeill, Katharine, Iwamoto, Fabio, Kreisl, Teri, Sul, Joohee, Shih, Joanna, Fine, Howard
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217817/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.38
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!